tiprankstipranks
Ajooni Biotech Limited (IN:AJOONI)
:AJOONI
India Market
Want to see IN:AJOONI full AI Analyst Report?

Ajooni Biotech Limited (AJOONI) AI Stock Analysis

0 Followers

Top Page

IN:AJOONI

Ajooni Biotech Limited

(AJOONI)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - Gpt-5.6Sol)
Rating:55Neutral
Price Target:
₹3.50
▼(-31.77% Downside)
Action:Reiterated
Date:07/16/26
The score is held back primarily by weak cash flow quality (multi-year negative operating cash flow and worsening free cash flow) despite strong revenue growth and a still-conservative balance sheet. Technicals are moderately supportive in the near term but not strong enough to offset the cash burn risk, while valuation is reasonable with a mid-teens P/E and no dividend yield support.
Positive Factors
Strong Revenue Growth
Accelerating revenue growth indicates improving scale and stronger demand for the company’s animal health and nutrition products. If sustained, broader sales can support operating leverage, expand distribution reach, and create a larger base from which to build future earnings and cash generation.
Negative Factors
Persistent Cash Burn
Repeated negative operating cash flow means reported earnings have not consistently converted into cash, while worsening free cash flow increases dependence on financing or balance-sheet resources. Unless cash conversion improves, growth may remain funding-intensive and execution flexibility could narrow.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Accelerating revenue growth indicates improving scale and stronger demand for the company’s animal health and nutrition products. If sustained, broader sales can support operating leverage, expand distribution reach, and create a larger base from which to build future earnings and cash generation.
Read all positive factors

Ajooni Biotech Limited (AJOONI) vs. iShares MSCI India ETF (INDA)

Ajooni Biotech Limited Business Overview & Revenue Model

Company Description
Founded in 2010, Ajooni Biotech Limited is an Indian enterprise primarily engaged in the production and distribution of animal nutrition products. Headquartered in Mohali, India, the company's offerings encompass specialized cattle feeds and vario...
How the Company Makes Money
Ajooni Biotech Limited primarily makes money by selling animal health and nutrition products (and related livestock/poultry-focused inputs) through its sales and distribution channels to customers in the animal husbandry ecosystem (e.g., farms, di...

Ajooni Biotech Limited Financial Statement Overview

Summary
Strong FY2026 revenue growth (~44% YoY) and a generally healthy balance sheet (debt-to-equity ~0.19) are positives, but they are outweighed by persistent cash weakness: operating cash flow has been negative for four straight years and free cash flow worsened sharply in FY2026, raising earnings quality and funding risk. Profitability is positive but thin (FY2026 net margin ~2.4%) with softening EBITDA margin (~3.4%).
Income Statement
73
Positive
Balance Sheet
78
Positive
Cash Flow
22
Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.15B1.82B1.15B801.15M744.88M740.38M
Gross Profit303.98M276.71M138.13M97.65M87.45M100.24M
EBITDA76.80M62.56M57.57M44.27M30.60M31.12M
Net Income39.59M43.22M32.38M21.61M11.25M10.49M
Balance Sheet
Total Assets1.25B1.20B950.51M475.20M587.31M290.18M
Cash, Cash Equivalents and Short-Term Investments3.74M4.19M68.30M4.30M4.93M573.86K
Total Debt269.11M177.63M19.40M21.68M51.77M53.50M
Total Liabilities332.86M291.74M69.72M48.12M170.62M126.35M
Stockholders Equity916.23M911.91M880.79M427.08M416.69M163.82M
Cash Flow
Free Cash Flow18.31M-232.32M-192.16M-95.54M-84.39M15.60M
Operating Cash Flow135.46M-52.03M-171.84M-39.52M-55.79M36.84M
Investing Cash Flow-122.77M-170.31M-171.34M76.37M-158.24M-18.97M
Financing Cash Flow71.88M158.23M248.26M-35.66M216.55M-19.73M

Ajooni Biotech Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.13
Price Trends
50DMA
3.83
Negative
100DMA
3.93
Negative
200DMA
4.15
Negative
Market Momentum
MACD
-0.10
Positive
RSI
34.77
Neutral
STOCH
16.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJOONI, the sentiment is Negative. The current price of 5.13 is above the 20-day moving average (MA) of 3.69, above the 50-day MA of 3.83, and above the 200-day MA of 4.15, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 34.77 is Neutral, neither overbought nor oversold. The STOCH value of 16.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AJOONI.

Ajooni Biotech Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
₹111.07B19.961.25%11.35%-8.27%
60
Neutral
₹13.04B11.410.52%39.75%186.91%
56
Neutral
₹9.12B13.9376.01%59.13%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
55
Neutral
₹602.85M15.4378.39%15.76%
53
Neutral
₹33.23B25.470.37%10.91%3.74%
47
Neutral
₹1.51B31.7117.76%-50.16%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:AJOONI
Ajooni Biotech Limited
3.47
-1.68
-32.62%
IN:AVANTIFEED
Avanti Feeds Limited
799.05
92.36
13.07%
IN:MKPL
M K Proteins Limited
4.02
-3.21
-44.40%
IN:MUKKA
Mukka Proteins Limited
32.07
4.51
16.36%
IN:PARAGMILK
Parag Milk Foods Ltd.
269.00
-8.40
-3.03%
IN:SKMEGGPROD
SKM Egg Products Export (India) Ltd.
241.35
70.89
41.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 16, 2026